Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series. - 2Slims down for Maintainable Weight reduction
- 3What's going around right now? COVID, flu, stomach bug on the rise
- 43D Printers for Specialists
- 5Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks
- Accomplishing Balance between fun and serious activities: Procedures for a Better Life
- Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide
- Favored Organic product for Seniors' Prosperity: Make Your Determination
- Step by step instructions to Pick the Right Dental specialist for Your Teeth Substitution
- Avoid Slam: Exploring the Pickup Truck Transformation
- Four countries to boycott Eurovision 2026 over Israel’s inclusion
- Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- Finding China: Four Urban areas for a Remarkable Excursion
